Seven years after the first gene-edited babies were revealed, biotech startup Manhattan Genomics is reviving the idea of ...

The inaugural TCCI AI-Driven Science Symposium was held in San Francisco from Monday to Tuesday, bringing together three ...

Explore how oligonucleotides are reshaping therapeutics, diagnostics and CRISPR with rapid, scalable and personalized solutions across biotech.

We are now in the second great wave of the genetic revolution, not defined by reading the human code of life, but by rewriting it.

Intellia Therapeutics has paused dosing in its Phase 3 MAGNITUDE trials after a patient experienced severe liver toxicity, as the company investigates and works with regulators on its CRISPR-based ...

To solve this critical challenge, he founded Nephrogen in 2022, a biotech startup that uses AI and advanced screening to ...

Discover Revvity, Inc.’s latest earnings, cloud growth, and $1B buyback. Click for my updated look at RVTY stock and why I ...

Intellia Therapeutics has temporarily paused dosing and screening for its phase 3 Magnitude and Magnitude-2 trials of Nex-z following a patient hospitalization, according to an Oct. 27 news release.

Intellia paused both trials after receiving a report of grade 4 liver enzymes and increased total bilirubin in a patient in ...

In a significant turn of events, Intellia Therapeutics has announced the temporary suspension of dosing and patient screening in two late-stage studies of its groundbreaking gene-editing treatment ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies ...